Evidence map›Paper›PMID 31739701›Full record

Observational studyInternational journal of audiology2020

Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis.

Nazanin Ghafari, Richard Court, Maxwell Tawanda Chirehwa, Lubbe Wiesner, Lucretia Petersen, Gary Maartens, Tawanda Gumbo, Helen McIlleron, Lebogang Ramma

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of audiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Nazanin GhafariDepartment of Health & Rehabilitation Sciences, University of Cape Town, Cape Town, South Africa.
Richard CourtDivision of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.
Maxwell Tawanda ChirehwaDivision of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-1685-4882
Lubbe WiesnerDivision of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.
Lucretia PetersenDepartment of Health & Rehabilitation Sciences, University of Cape Town, Cape Town, South Africa.ORCID 0000-0001-9385-4731
Gary MaartensDivision of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0003-3080-6606
Tawanda GumboBaylor Research Institute, Baylor University Medical Center, Dallas, TX, USA.
Helen McIlleronDivision of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.
Lebogang RammaDepartment of Health & Rehabilitation Sciences, University of Cape Town, Cape Town, South Africa.ORCID 0000-0001-9109-9103
University of Cape Town · ZABaylor University Medical Center · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
Pharmacometric optimization of second line drugs for MDR tuberculosis treatmentR01AI116155 · NIAID · UNIVERSITY OF CAPE TOWN · PI GUMBO, TAWANDA, MCILLERON, HELEN · 2015 to 2019
$1.7M
NIAID NIH HHS R01 AI116155NIAID NIH HHS U01 AI068632NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI106716Wellcome TrustWellcome Trust 206379/Z/17/Z
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAnti-Bacterial AgentsAudiometryFemaleHearing LossHumansIncidenceKanamycinMaleMiddle AgedOtotoxicityProspective StudiesRisk FactorsSouth AfricaTuberculosis, Multidrug-ResistantAnti-Bacterial AgentsKanamycinaminoglycosidesAUCCochleotoxicityhearing losskanamycinpharmacokinetics

Identifiers

PMID31739701
PMCPMC7582222
OpenAlexW2990385844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.